Venture Capital

Xconomy: Annexon Adds On $100M To Advance Antibodies To Treat Neurodegeneration

by posted 2months ago 34 views
Annexon Biosciences, a biotech founded in late 2014 by former Elan Pharmaceuticals executives, has added $100 million to its coffers to move its two clinical-stage programs along and to continue advancing its preclinical pipeline. The South San Francisco-based company is developing drugs for patients with autoimmune and neurodegenerative disorders that are caused by an abnormal […]